WO2008021536A3 - Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects - Google Patents

Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects Download PDF

Info

Publication number
WO2008021536A3
WO2008021536A3 PCT/US2007/018340 US2007018340W WO2008021536A3 WO 2008021536 A3 WO2008021536 A3 WO 2008021536A3 US 2007018340 W US2007018340 W US 2007018340W WO 2008021536 A3 WO2008021536 A3 WO 2008021536A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
beta
alpha
reduction
tau
Prior art date
Application number
PCT/US2007/018340
Other languages
French (fr)
Other versions
WO2008021536A2 (en
Inventor
Chih-Ping Liu
Original Assignee
Pepgen Corp
Chih-Ping Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepgen Corp, Chih-Ping Liu filed Critical Pepgen Corp
Publication of WO2008021536A2 publication Critical patent/WO2008021536A2/en
Publication of WO2008021536A3 publication Critical patent/WO2008021536A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

A method of treating conditions responsive to therapy with interferon-alpha o interferon-beta is provided, where the dose of interferon-alpha or interferon-beta i increased and a dose of interferon-tau is additionally administered. The method results in efficacious thera with a reduction in unwanted adverse events.
PCT/US2007/018340 2006-08-18 2007-08-16 Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects WO2008021536A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83859906P 2006-08-18 2006-08-18
US60/838,599 2006-08-18

Publications (2)

Publication Number Publication Date
WO2008021536A2 WO2008021536A2 (en) 2008-02-21
WO2008021536A3 true WO2008021536A3 (en) 2008-04-17

Family

ID=38996365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018340 WO2008021536A2 (en) 2006-08-18 2007-08-16 Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects

Country Status (1)

Country Link
WO (1) WO2008021536A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013165963A1 (en) * 2012-05-03 2013-11-07 Amarillo Biosciences, Inc. Treatment of thrombocytopenia using orally administered interferon
WO2021216801A1 (en) * 2020-04-22 2021-10-28 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030012766A1 (en) * 1989-03-02 2003-01-16 University Of Florida Orally-administered interferon-tau compositions and methods
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030012766A1 (en) * 1989-03-02 2003-01-16 University Of Florida Orally-administered interferon-tau compositions and methods
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them

Also Published As

Publication number Publication date
WO2008021536A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
IL171607A (en) Use of a botulinum toxin for the preparation of a medicament for treating sinus headache
WO2008063727A3 (en) Combination therapy for treatment of viral infections
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
EP2583680A3 (en) Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
WO2004026303A3 (en) Use of posaconazole for the treatment of fungal infections
WO2004002999A3 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
CA2516333A1 (en) Drug for reducing side effects in ribavirin / interferon combination therapy
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
WO2007098106A3 (en) Respiratory tract delivery of interferon-tau
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2005011579A3 (en) Treatment of dependence withdrawal
WO2005092303A3 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11
WO2004071397A3 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
WO2005087255A3 (en) Method of optimizing treatment with interferon-tau
WO2008021536A3 (en) Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects
MD2549G2 (en) Method of treatment of the chronic viral hepatitis C
BR0307022A (en) Method of treating a patient who needs analgesia
WO2006091222A3 (en) Methods of treating and preventing severe acute respiratory syndrome (sars) with avr118
HK1055689A1 (en) Treatment of hepatitis c with thymosin, interferonand ribavirin
James Ribavirin approved for hepatitis C combination treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811417

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07811417

Country of ref document: EP

Kind code of ref document: A2